Crizotinib is a key treatment option for ALK/ROS1-positive non-small cell lung cancer, ALK-positive anaplastic large cell lymphoma, and inflammatory myofibroblastic tumors. Its standardized use and authenticity are directly related to therapeutic efficacy and safety. Due to the complex drug interactions and specific adverse reactions of this medication, patients must obtain it through legal channels and master essential risk prevention and control knowledge.

Purchasing Channels for Crizotinib

Overseas Purchasing

Patients may choose to consult and purchase Crizotinib at hospital pharmacies or legitimate drugstores in countries or regions where the drug has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make budgets and plans in advance before purchasing.

Purchasing through Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions usually provide legal import channels and offer professional consultation and guidance.

Precautions for Crizotinib

Pre-Medication Contraindication Screening

Use is prohibited in patients allergic to the active ingredient or any excipients.

Concomitant use with strong CYP3A inhibitors (such as ketoconazole) is contraindicated.

Specifications for Using Special Dosage Forms

Capsules: Must be swallowed whole; chewing, crushing, or splitting is prohibited.

Oral Microparticles: Must be completely removed from the capsule shell before administration; swallowing with the shell is strictly forbidden. The total amount of microparticles per single dose must not exceed that contained in 4 capsule shells.

Hepatotoxicity Monitoring

Incidence rate: 11% of patients experience ALT levels exceeding 5 times the upper limit of normal.

Monitoring frequency: Liver function should be tested every 2 weeks in the first 2 months before treatment, and then monthly thereafter.

Interstitial Lung Disease/Pneumonitis

Onset time: Most cases occur within 3 months of starting treatment.

Symptom recognition: Symptoms such as dyspnea, productive cough, and fever must be reported immediately.

Authentication of Crizotinib

Verification of Packaging Features

The outer packaging must clearly indicate the manufacturer information of Pfizer Inc. (U.S.).

Verify the correspondence between the U.S. National Drug Code (NDC) and the drug specification.

Key Identification Points for Capsules

200mg specification: Opaque white body/opaque pink cap. The cap is printed with "Pfizer" and the body with "CRZ200".

250mg specification: Opaque pink body and cap. The cap is printed with "Pfizer" and the body with "CRZ250".

Identification Features for Oral Microparticles

20mg specification: Opaque white body/opaque light blue cap.

50mg specification: Opaque light gray body/opaque gray cap.

150mg specification: Opaque light blue body and cap.

Official Verification Channels

Enter the import drug registration certificate number in the "Drug Query" section on the official website of the National Medical Products Administration.

Scan the drug packaging traceability code to verify circulation information.